208 related articles for article (PubMed ID: 31406196)
1. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
3. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
5. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
Pu X; Shi J; Li Z; Feng A; Ye Q
Pathol Res Pract; 2015 Jun; 211(6):421-5. PubMed ID: 25818873
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
8. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
9. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
10. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Marchiò C; Lambros MB; Gugliotta P; Di Cantogno LV; Botta C; Pasini B; Tan DS; Mackay A; Fenwick K; Tamber N; Bussolati G; Ashworth A; Reis-Filho JS; Sapino A
J Pathol; 2009 Sep; 219(1):16-24. PubMed ID: 19670217
[TBL] [Abstract][Full Text] [Related]
11. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
12. The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas.
Ji H; Xuan Q; Nanding A; Zhang H; Zhang Q
PLoS One; 2015; 10(7):e0132824. PubMed ID: 26161550
[TBL] [Abstract][Full Text] [Related]
13. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
14. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
16. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
17. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
Davies V; Voutsadakis IA
Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
[No Abstract] [Full Text] [Related]
18. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort.
Koudelakova V; Trojanec R; Vrbkova J; Donevska S; Bouchalova K; Kolar Z; Varanasi L; Hajduch M
Genes Chromosomes Cancer; 2016 May; 55(5):409-17. PubMed ID: 26847577
[TBL] [Abstract][Full Text] [Related]
19. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z
Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611
[TBL] [Abstract][Full Text] [Related]
20. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]